N/A N=99 Platelet Function in Resuscitated Patients
Acute ST Segment Elevation Myocardial Infarction
Primary: Platelet Inhibition Measured With Optical Aggregometry — 109; 253.8 AU*min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=246 Platelet Activity in Vascular Surgery and Cardiovascular Events
Cardiovascular Disease · Peripheral Artery Disease · Critical Limb Ischemia
Primary: Number of Patients in Which Platelet Activity Measurements Were Associated With Short-term Cardiovascular Events — 31; 16 participants
N/A N=310 Evaluation of Trima Version 7.0 Platelets in 100% Plasma
Healthy Volunteers
Primary: Number of Participants With Platelet Units Containing an Acceptable Residual WBC Level — 92; 93; 93; 1 Participants
N/A N=335 Evaluation of Trima Version 7.0 Platelets in PAS
Healthy Volunteers
Primary: Number of Participants With Platelet Units Containing an Acceptable Residual WBC Level — 93; 93; 93; 0 Participants
Phase 2 N=44 Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction
Myocardial Infarction
Primary: Bleeding Time — 1020; 1020 seconds
Phase 2 N=27 Targeting Platelets in Chronic HIV Infection
HIV-1 Infection
Primary: Change in sCD14 From Baseline to Week 24 — 35.75; -251.40; -101.75 pg/mL
Phase 3 N=1,351 Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Thrombocytopenia
Primary: At Least One Day With Grade 2 or Higher Bleeding — 304; 293; 299; 142 participants — p=0.83
Phase 2 N=40 Effects of Pioglitazone on Platelet Function
Diabetes · Platelet Function · Healthy
Primary: Percent Platelet Aggregation Induced by Arachidonic Acid — 80; 90; 60; 29 maximum percentage aggregation
Phase 4 N=46 Platelet Transfusion During Neonatal Open Heart Surgery
Cardiac Disease · Cardiac Surgery · Cardiopulmonary Bypass
Primary: Amount of Blood Products Transfused — 58; 103 milliliter per kilogram (mL/kg)
Phase 2 N=55 Antiplatelet Therapy in HIV
HIV · Cardiovascular Diseases · Inflammation
Primary: Percentage Platelet Aggregation in PRP After Stimulation With Arachidonic Acid 1600 μM for 5 Min — 72.35; 79.11; 72.79; 26.77 %aggregation
Phase 1 N=48 Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study
Chronic Kidney Disease
Primary: Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid — 21.0; 18.0; 0; 0 ohms
Phase 1 N=28 Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets
Thrombocytopenia
Primary: Adverse Events (AEs) by Level of Severity — 8; 18; 6; 21 adverse events
Phase 4 N=60 Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction
Myocardial Infarction
Primary: Concentration of Platelet Extracellular Vesicles/ml — 2690000; 4310000 Platelet Extracellular Vesicles/mL
Phase 2 N=200 Cold Stored Platelet in Hemorrhagic Shock
Trauma · Hemorrhage
Primary: Study Feasibility — 91; 82 Participants
N/A N=445 Platelet Count Trends in Pre-eclamptic Parturients
Obstetric Labor Complications · Preeclampsia · Thrombocytopenia
Primary: Positive Predictive Value of Earliest Available Platelet Count — 99; 90; 100 percentage of positive platelet counts
N/A N=22 Survival and Recovery of Radio-labeled Platelets Derived From Mirasol-treated Whole Blood
Blood Safety
Primary: Platelet 24-hour Relative Recovery — 43.31; 52.01 Percentage of platelet count
N/A N=21 Study of the Effect of Differing Platelet Transfusion Times in Neonates
Thrombocytopenia
Primary: Change in Post-transfusion Platelet Counts — 99; 97.5 Platelets (*10^3/mm^3) — p=0.8
Phase 1 N=24 Thrombosomes® in Bleeding Thrombocytopenic Patients
Thrombocytopenia · Hematologic Diseases · Bone Marrow Aplasia
Primary: Number of Patients With Treatment-Emergent Adverse Events (TEAE) — 7; 6; 5 Participants
N/A N=60 Impact of Ticagrelor Re-load on Pharmacodynamic Profiles
Coronary Artery Disease
Primary: Platelet Reactivity Index (PRI) by Vasodilator-stimulated Phosphoprotein (VASP) — 17.87; 23.4 PRI%
Phase 2 N=10 Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
Thrombocytopenia · Alloimmune Platelet Refractoriness
Primary: Number of Subjects With Sustained Platelet Transfusion Responsiveness — 4 Participants
N/A N=177 Microparticles in Stored RBC as Potential Mediators of Transfusion Complications
Coronary Artery Bypass
Primary: In Hospital Mortality — 0; 4 participants — p=0.142
N/A N=14 Impact of Hypoglycaemia in Patients With Diabetes Mellitus Type 2 on Platelet Activation
Diabetes Mellitus With Hypoglycemia · Diabetes Mellitus, Type 2 · Hypoglycemia
Primary: Changes in Platelet Activation Marker Adenosin Diphosphate (%) — 63; 64.4; 64.4; 61.1 percentage of ADP
N/A N=100 Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia
Leukemia, Myeloid, Acute · Leukemia, Lymphoblastic, Acute
Primary: Survial Rate at 30 Days — 100; 97 percentage of participants
N/A N=27 The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization
Coronary Artery Disease · Chest Pain
Primary: The Percentage of Coated Platelets After the Administration of Clopidogrel in Patients Undergoing Cardiac Catheterization and/or Angioplasty — 32.8 Percent of platelets…
Phase 2 N=14 Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept
Intracerebral Hemorrhage
Primary: Change in Platelet Activity, Measured in Seconds on PFA-EPI Assay, From Pre to Post-treatment — 68 seconds — p=0.014
N/A N=184 Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery
Bleeding
Primary: Calculated Blood Loss — 1996 milliters
Phase 4 N=20 Reversing Ticagrelor's Effects With Fresh Platelets
Coronary Artery Disease
Primary: P2Y12 Reaction Unit (PRU) — 284.1; 284.1; 39.1; 37.5 PRU
N/A N=50 The Impact of Storage Techniques on Platelets Number and Function After Acute Normovolemic Hemodilution (ANH)
Cardiac Surgical Procedures
Primary: Time to Platelet Aggregation as Measured Using Collagen-epinephrine (EPI) — 260; 261 seconds
Phase 4 N=87 P3AMI Antiplatelet Trial
Heart Attack
Primary: Pharmacodynamic Assessment of Degree of Platelet Inhibition as Determined by Verify Now Point of Care Assay and Expressed as P2Y12 Reaction Units (PRU) — 270.23; 247.73…
N/A N=334 Platelet Reactivity (High On-Treatment Platelet Reactivity) as Guidance for APT (Antiplatelet Therapy) Adjustment After PCI (Percutaneous Coronary Intervention)
PRU(Platelet Reactivity Unit) · APT(Antiplatelet Therapy) · HOTPR(High on Treat Platelet Reactivity)
Primary: Numbers of Participants With MACE(Major Adverse Cardiac Event) of Study Subjects — 1; 1; 2 numbers of participants with MACE — p=0.002